Glenmark gets FDA approval to market generic anti-convulsant Gabapentin

By Lisa Kerner

Charlotte, N.C., Aug. 24 - Glenmark Pharmaceuticals Ltd. said its wholly owned U.S. subsidiary, Glenmark Pharmaceuticals, Inc., received Food and Drug Administration approval to market the anti-convulsant Gabapentin oral tablets 600 mg and 800 mg to help control epileptic seizures.

Shipment of the product is expected to begin immediately.

Gabapentin, also used to relieve pain and in the treatment of psychiatric disorders, has an estimated generic market of $328 million, according to a company news release.

This latest approval brings to 10 the total number of generic products Glenmark has on the market.

Glenmark is a biopharmaceutical company based in Mumbai, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.